The Japanese company Astellas Pharma has announced a fall of 18.2% of its current quarterly earnings and sharply reduced its annual earnings forecast, to take into account the cost of a license extension and the impact of yen appreciation .
Astellas said it would again cut its earnings outlook after the publication of its results for the period July to September when he must account for costs of the acquisition of OSI Pharmaceuticals to four billion dollars (3, 25 billion euros).
While he has spent 165 million dollars to use technology to antibiotics Regeneron Pharmaceuticals, the Japanese second largest pharmaceutical company reported as part of its first fiscal quarter ended June from a current profit of 56.94 billion yen (502 million euros).
The group, sometimes mentioned as a possible white knight for Genzyme to counter a possible bid from Sanofi-Aventis, has reduced its profit forecast for its current fiscal year 2010-2011 to 136 billion yen, against 155 million previously planned, and 144 billion yen under the Thomson Reuters consensus I / B / E / S.
If it materializes, this forecast would show a decrease of 28.8% of profit compared to last year and would be the second consecutive year of declining profits.